These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32895485)

  • 1. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
    Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC
    Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the molecular determinants of the SARS-CoV-2 attack.
    Kanduc D; Shoenfeld Y
    Clin Immunol; 2020 Jun; 215():108426. PubMed ID: 32311462
    [No Abstract]   [Full Text] [Related]  

  • 5. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
    Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
    Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
    Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
    Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Du S; Cao Y; Zhu Q; Yu P; Qi F; Wang G; Du X; Bao L; Deng W; Zhu H; Liu J; Nie J; Zheng Y; Liang H; Liu R; Gong S; Xu H; Yisimayi A; Lv Q; Wang B; He R; Han Y; Zhao W; Bai Y; Qu Y; Gao X; Ji C; Wang Q; Gao N; Huang W; Wang Y; Xie XS; Su XD; Xiao J; Qin C
    Cell; 2020 Nov; 183(4):1013-1023.e13. PubMed ID: 32970990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
    Vojdani A; Kharrazian D
    Clin Immunol; 2020 Aug; 217():108480. PubMed ID: 32461193
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
    Wan J; Xing S; Ding L; Wang Y; Gu C; Wu Y; Rong B; Li C; Wang S; Chen K; He C; Zhu D; Yuan S; Qiu C; Zhao C; Nie L; Gao Z; Jiao J; Zhang X; Wang X; Ying T; Wang H; Xie Y; Lu Y; Xu J; Lan F
    Cell Rep; 2020 Jul; 32(3):107918. PubMed ID: 32668215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.
    Liu B; Shi Y; Zhang W; Li R; He Z; Yang X; Pan Y; Deng X; Tan M; Zhao L; Zou F; Zhang Y; Pan T; Zhang J; Zhang X; Xiao F; Li F; Deng K; Zhang H
    Cell Mol Immunol; 2020 Oct; 17(10):1098-1100. PubMed ID: 32939033
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
    Xu W; Wang M; Yu D; Zhang X
    Front Immunol; 2020; 11():565278. PubMed ID: 33013929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
    Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
    Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.